Relacorilant, a selective glucocorticoid receptor modulator, is showing promise when combined with nab-paclitaxel (Abraxane) for patients with platinum-resistant ovarian cancer. This therapeutic strategy is being explored as a novel approach to address this difficult-to-treat malignancy.
Phase 2 Trial Data
Data from a phase 2 trial (NCT03776812) have provided encouraging results, supporting the continued investigation of relacorilant in this setting. Premal Thaker, MD, MS, from Washington University in St. Louis and the Siteman Cancer Center, discussed the rationale and findings in an interview, highlighting the potential of this combination to improve outcomes for patients with platinum-resistant ovarian cancer.
ROSELLA Trial
Building on the phase 2 findings, the phase 3 ROSELLA trial (NCT05257408) is currently underway. This trial aims to further evaluate the efficacy and safety of relacorilant plus nab-paclitaxel in a larger patient population. The outcomes of the ROSELLA trial are eagerly anticipated, as they could potentially establish a new standard of care for this patient group.
Mechanism of Action
Relacorilant's mechanism of action, as a selective glucocorticoid receptor modulator, offers a unique approach to treating ovarian cancer. By targeting the glucocorticoid receptor, relacorilant aims to disrupt pathways that contribute to cancer growth and resistance to chemotherapy. This targeted approach may provide benefits in overcoming resistance mechanisms commonly observed in platinum-resistant ovarian cancer.
